Yahoo · Oct 19, 2026
Sector Update: Healthcare Stocks Softer Monday Afternoon
Healthcare stocks fell Monday afternoon with the NYSE Healthcare Index declining 0.6% and the State
RA
NASDAQ · RARE
Ultragenyx Pharmaceutical Inc.
Healthcare · Biotechnology
$16.10
Down-$0.68 (-4.05%)
Updated Nov 1, 2026, 5:23 AM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.49B
- P/E ratio
- -6.23
- Dividend yield
- 0.00%
- 52-week range
- $12.73 – $39.89
- Volume
- 2.33M
- Avg. volume
- 1.5M
Price performance · RARE
RARE price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
RARE closed at $16.10 after 20 trading sessions, up 11.03% for the selected period.
- Last close
- $16.10
- Period change
- +11.03%
- Period low
- $14.46
- Period high
- $17.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $16.64 | $16.9299 | $15.92 | $16.10 | 2.33M |
| Oct 29, 2026 | $17.26 | $17.625 | $16.71 | $16.78 | 2.8M |
| Oct 28, 2026 | $16.73 | $17.3499 | $16.4734 | $17.20 | 2.32M |
| Oct 27, 2026 | $16.05 | $16.96 | $15.88 | $16.75 | 4.94M |
| Oct 26, 2026 | $15.75 | $16.22 | $15.59 | $16.08 | 3.02M |
| Oct 23, 2026 | $15.92 | $15.94 | $15.49 | $15.65 | 1.79M |
| Oct 22, 2026 | $15.78 | $16.25 | $15.60 | $15.95 | 2.37M |
| Oct 21, 2026 | $16.02 | $16.31 | $15.785 | $15.92 | 2.83M |
| Oct 20, 2026 | $15.01 | $16.27 | $14.99 | $16.02 | 3.55M |
| Oct 19, 2026 | $14.67 | $15.08 | $14.535 | $15.07 | 2.98M |
| Oct 16, 2026 | $15.11 | $15.21 | $14.44 | $14.54 | 2.93M |
| Oct 15, 2026 | $14.87 | $15.37 | $14.79 | $15.17 | 3.33M |
| Oct 14, 2026 | $14.93 | $15.18 | $14.67 | $14.90 | 2.96M |
| Oct 13, 2026 | $15.27 | $15.39 | $14.69 | $14.92 | 5.31M |
| Oct 12, 2026 | $15.42 | $15.49 | $15.10 | $15.30 | 2.9M |
| Oct 9, 2026 | $15.30 | $15.73 | $15.23 | $15.48 | 2.93M |
| Oct 8, 2026 | $14.79 | $15.52 | $14.43 | $15.29 | 5.4M |
| Oct 7, 2026 | $14.37 | $15.2532 | $14.345 | $14.89 | 4.16M |
| Oct 6, 2026 | $14.60 | $14.70 | $14.08 | $14.46 | 3.89M |
| Oct 5, 2026 | $15.25 | $15.31 | $14.21 | $14.50 | 4.66M |
Latest RARE news
The latest Smart Investors Daily articles mentioning RARE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RARE research
Overview
Company profile and research snapshot.
Company profile
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $50.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | UBS | Neutral | — |
| Sep 21, 2026 | Evercore ISI Group | In-Line | — |
| Sep 21, 2026 | Barclays | Overweight | — |
| Sep 18, 2026 | Morgan Stanley | Equal-Weight | — |
| Sep 18, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 19, 2026
Ultragenyx Settles DOJOLVI Patent Litigation With Navinta, Allowing Generic Entry Starting January 1, 2033; Or July 2033 With Pediatric Exclusivity; Similar Patent Litigation Against Other DOJOLVI Abbreviated New Drug Application Filers Related To DOJOLVI Remains Pending
On October 19, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") and Baylor Research Institute ("BRI") entered into a settlement agreement with Navinta LLC ("Navinta") resolving patent
Benzinga · Oct 15, 2026
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16
UBS analyst Joon Lee initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral rating and announces Price Target of $16.
Yahoo · Oct 14, 2026
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
